计划状态
招聘阶段
第二阶段允许先接受免疫治疗
没有CRC 指导的试验
是标签
MSI-H/ MMRd、MSS/ MMRp评论
Trial in China, for for first-line treatment of metastatic colorectal cancer.
Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy.
Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
SSGJ-707: an experimental anti PD-1 x VEGF bispecific antibody (similar to pembrolizumab plus bevacizumab).
| 地点 | 位置状态 |
|---|---|
| 中国 | |
|
Liu Tianshu Shanghai, Shanghai |
招聘 |
联系方式
纳入标准
纳入标准
1. Males and/or females over age 18
2. Histologically and/or cytologically documented metastatic colorectal cancer confirmed .
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Expected survival >=12 weeks.
5. Signed informed consent form.
排除标准
排除标准：
1. Known uncontrolled or symptomatic central nervous system metastatic disease.
2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
3. Inadequate organ or bone marrow function.
4. Pregnant or breast-feeding woman.
5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
